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Abstract
Purpose: To determine the hemostatic response after acute aerobic exercise in Obstructive
Sleep Apnea (OSA). Methods: Eighteen males were recruited from the university and local
community. Individuals who presented evidence of cardiovascular, pulmonary, or
metabolic disease were excluded. Apnea-Hypopnea Index (AHI) > 5 was criteria for OSA.
Subjects performed a treadmill exercise test at 35% and 70% predicted VO2reserve during
the morning hours. Pre exercise blood samples were obtained after 15 minutes supine rest
and within two minutes following exercise. Repeated Measures ANOVA were performed
for Factor VIII antigen, tPA antigen, tPA activity, and PAI-1 activity across two time points
(Pre vs. Post) and between conditions (OSA vs. Controls). Correlational analysis compared
all hemostatic factors with age, BMI, and AHI. Results: Mean AHI was (13.00 + 12.6)
indicating mild OSA severity. There were no exercise x condition interaction for any
observed hemostatic markers (P > 0.05). There was a significant main effect for exercise
in Factor VIII, tPA antigen, and tPA activity in both groups (P < 0.05). There was no main
effect for OSA except an observed trend in PAI-1 which remained elevated after exercise
(P = 0.05). FVIII:Ag and BMI (R = .520), tPA:Ag and AHI (R = .489), and tPA:Ag and
age (R = .496) were positively correlated (P < 0.05). Conclusion: The hemostatic response
after acute aerobic exercise is unaffected in mild OSA although PAI-1 activity seems to be
elevated impacting fibrinolytic potential. BMI seems to correlate with FVIII:Ag, while
AHI and age correlate with tPA:Ag.

Keywords: Hemostasis, Obstructive Sleep Apnea, acute exercise, coagulation, fibrinolysis
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Chapter 1
Introduction
Obstructive Sleep Apnea (OSA) is highly prevalent across populations and appears
to affect approximately 2 - 4 % of the middle aged adults (38). An estimated 85% of
individuals with clinically significant OSA are undiagnosed with a large impact on males
(28, 51). OSA is characterized by repetitive interruptions of ventilation during sleep due to
a complete cessation of airflow or a significant decrease in airflow with a concurrent
decrease in oxygen saturation (53). Patients with OSA exhibit reductions in the size of the
pharyngeal airway directly due to obesity; and/or other obstacles including bone and soft
tissues (38, 61). Children may also be affected by this condition due to tonsils and adenoids
(53). During wakefulness, greater activation of the pharyngeal dilator muscles results in a
patent airway that is less likely to collapse (36). However, during sleep, activation is
reduced to the upper airway dilator muscles promoting collapse and consequent arousal
(36). Increasing arousal during sleep contributes to excessive daytime sleepiness that could
lead to other negative outcomes (53).
OSA has been associated with numerous health conditions and several risk factors
may predispose individuals to develop the condition. Risk factors include genetic factors
that affect the craniofacial anatomy (35), age, sex, obesity (45), pregnancy, diabetes, and
hypothyroidism (52). Many environmental factors also influence this risk such as smoking
and alcohol use (45). OSA is a risk factor itself for the development of other diseases such
as hypertension, heart failure, arrhythmias, CAD, and stroke (28). Signs of OSA include
disturbed sleep (snoring and restlessness), daytime fatigue, and irregular breathing patterns
during sleeping hours, choking sensations when wakened, and morning headaches (35, 10).
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The diagnosis of OSA is most commonly determined using a multi-channel
analysis (polysomnography) utilizing an EEG, EOG, ECG, and oximetry along with an
extensive physical and medical history examination (8). The readily accepted diagnosis for
the disorder is defined as five or more apnea-hypopneas per hour of sleep (> 5 AHI)
(43,38,8). Apnea is defined as a complete cessation of airflow greater than or equal to ten
seconds (> 10 s) while hypopnea is a decrease in airflow of at least 50 %, lasting at least
ten seconds (> 10 s), and accompanied by at least a 4 % decrease in oxygen saturation (8).
Although discrepancies with the definition of a hypopnea and the concomitant decrease in
oxygen saturation exist, a reduction of at least 4 % shows the greatest association with
cardiovascular disease compared to higher saturations (44).
It has been well established that the presence of OSA is associated with a greater
incidence of cardiovascular disease (CVD), which increases with disease severity (40, 50,
30, 63, 55, 41,). Marshall et al. reported moderate to severe OSA to be independently
associated with increased risk of all-cause mortality, stroke and cancer after a 20 year
follow-up (30). Results also show that efficient treatment of OSA has a beneficial impact
on the disease and the subsequent CVD risk (29, 64). Similarly, Marin et al. reported the
odds ratio of fatal or non-fatal cardiovascular events with patients under CPAP treatment
were not significantly different than simple snorers and mild-moderate untreated persons
(29). Previous studies have shown that sleep disordered breathing (SDB) contributes to the
initial progression of atherosclerosis, suggesting OSA may be an independent risk factor
for CVD incidence (5, 16, 19). In particular, Fox et al. found that increasing OSA severity
was linked to a greater carotid intima-media thickness (CIMT) without the presence of
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CVD or common risk factors compared to matched controls (19). Therefore, OSA may
have a mechanistic role in the progression of cardiovascular disease.
Hemostasis is balanced by two mechanisms: coagulation, otherwise known as
blood clotting, and fibrinolysis, the dissolution of a blood clot. Coagulation incorporates
two pathways of activation that eventually result in the formation of thrombin and blood
clot. Shortly after the Second World War, Davie and Ratnoff discovered a ‘waterfall’ like
sequence of enzymes acting as substrates to other activated enzymes that lead to the
formation of a stable fibrin clot (15). This proposed sequence is independent of factors
extrinsic to the blood and is known as the intrinsic pathway. The intrinsic pathway is
initiated by the activation of Factor XII which sequentially activates Factor XI which
further activates Factor IX. In the presence of Factor VIII, Factor IX then activates Factor
X which forms a complex with prothrombin generating thrombin (37). The extrinsic
pathway is initiated through a subendothelial derived enzyme, Tissue Factor. In the event
of vessel damage, Tissue Factor reacts in the presence of Factor V which further activates
the reaction of Factor X and prothrombin (37). The common pathway has been described
as the pathway where the intrinsic and extrinsic pathways overlap. The activation of Factor
X and the subsequent generation of thrombin compose much of the common pathway
(Figure 1). Thrombin is a key enzyme that contributes to platelet activation, fibrinogen
conversion to fibrin, and amplification (12, 14). Thrombin also causes a feedback loop and
activation of Factor XIII which stabilizes the unstable fibrin creating a firm meshwork of
fibrin that will compose of much of the clot (37).
Fibrinolysis consists of degradation of fibrin by a serine protease, plasmin.
Proteolytic enzymes, known as plasminogen activators, react with plasminogen to generate
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plasmin. This most important known activators are tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) produced by the endothelium (7). uPA has
a lower affinity for plasminogen and therefore much of the process of plasmin formation
is performed by tPA (9). These activators have particularly short half-lives (approximately
4 – 8 minutes) as they are either cleared by the liver or inactivated by inhibitors (9). The
most common of these inhibitors are Plasminogen Activator Inhibitor-1 (PAI-1),
Plasminogen Activator Inhibitor-2 (PAI-2), and α2-antiplasmin (54). The functional
balance between coagulation and fibrinolysis is of the upmost importance so the circulation
can remain in a closed circuit without either excessive clotting or bleeding.
Much of the clinical evidence suggests greater coagulation potential and lower
fibrinolytic activity in individuals with CVD (23, 20, 31). Folsom et al. found that markers
of coagulation potential, Factor VIII and von Willebrand Factor (vWF), are associated with
cardiovascular disease in both men and women (18). Specifically, increased FVIII and
vWF have also been associated with higher incidence of ischemic heart disease and
endothelial dysfunction (23, 18, 32, 49, 57). Further, Tracy et al. indicated that Factor VIII
was significantly associated with coronary heart disease (CHD) and mortality in men and
stroke/transient ischemic attacks in women (57). In the Northwick Park Heart Study,
researchers found decreased fibrinolytic activity to be the main determinant of ischemic
heart disease in younger men (31). Thogersen et al. showed that elevated plasma levels of
PAI-1 and tPA antigen were associated with a first acute myocardial infarction for men
and women (56). These studies indicate the clinical importance of hemostatic variables and
the role in CVD.
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Individuals with OSA exhibit an altered hemostatic balance. Guardiola et al.
observed decreased whole blood clotting time in individuals with untreated OSA both
before sleep and upon waking (22). The hypoxic environment associated with OSA may
explain this prothrombotic state (60). Furthermore, it appears the prothrombotic state is
due to a decrease in fibrinolytic activity rather than an increase in coagulation factors (6,
47). However, evidence also suggests that hypoxic conditions result in a shortened
coagulation time with a concurrent rise in Factor VIII (6). PAI-1 is positively associated
with AHI, and oxygen saturation (SpO2) suggesting disease severity contributes to reduced
fibrinolytic activity (59, 60, 65). Von Kanel et al. reported a higher AHI and increased time
spent below 90 % SpO2 were associated with higher PAI-1 levels in relatively healthy
populations (60). A possible mechanism for this relationship is the up regulation of PAI-1
transcription with concomitant increases in PAI-1 mRNA stability during hypoxia, which
is exacerbated by low tPA expression (42).
Many instances of myocardial infarction are preceded by physical exertion (21,34).
Acil et al. found that persons with coronary artery disease exhibit a hemostatic balance
favoring greater coagulation after an acute bout of exercise (1). This could be
mechanistically linked with exertion-related ischemic events as occlusive thrombi are
responsible for a greater portion of exertion –related events than events triggered by other
causes (21). Myocardial infarctions seem to occur more frequently in sedentary individuals
after physical exertion, particularly when the activity is strenuous (21, 34). During exercise,
both coagulation and fibrinolysis increase proportional to intensity (33). Early research
showed an elevation in coagulation potential during exercise, particularly due to an
increase in Factor VIII (26, 11, 3, 4). Cohen et al. suggested that the exercise-induced rise
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in Factor VIII is partially explained through beta-adrenergic-receptor stimulation (11).
There is also a concomitant increase in fibrinolysis, due to increases in tPA and decreases
in PAI-1 (26, 11, 3, 17, 4, 24, 48, 27, 43, 61, 13, 62) which change in proportion to the
intensity of exercise (24, 48, 62). Following exercise, there is evidence for a prothrombotic
state as markers of coagulation potential remain elevated for an hour into the post-exercise
period (39), while a significant decrease in fibrinolytic potential occurs within 10 minutes
(13, 39).
Although hemostatic responses to exercise are clinically important, these responses
are relatively unknown in obstructive sleep apnea patients. Rangemark et al. found that
OSA subjects exhibited increases in PAI-1 activity with values remaining significantly
elevated before and after 4 minutes of submaximal cycle ergometer exercise compared to
matched controls (46). After exercise, tPA showed a four-fold increase but did not
significantly differ between groups (46). However, this study did not analyze any factors
of coagulation other than platelet activity, which did not significantly change (46). The aim
of this study is to determine if acute aerobic exercise increases Factor VIII, tPA antigen
and PAI-1 activity with concurrent decreases in tPA activity in obstructive sleep apnea
patients.
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Chapter 2
Methods
Subjects
All subjects gave informed written consent on the study protocol approved by the
James Madison University Institutional Review Board. OSA subjects were recruited from
the JMU community and Sentara Rockingham Memorial Hospital (SRMH) Sleep Clinic.
All SRMH subjects were diagnosed with sleep apnea and not currently using continuous
positive airway pressure (CPAP) as treatment. Eighteen males (> 18 years of age) with
observed sleep problems or significant snoring were recruited for the present study.
Mobility issues, and/or evidence of cardiovascular, pulmonary, and metabolic diseases were
criteria for exclusion in both OSA and Non-OSA groups. Demographic data is presented in
Table 1 for OSA and Normal individuals.
To establish likelihood of Sleep Apnea and screen for exclusion criteria in
community-recruited participants, administration of established sleep surveys including
Berlin Questionnaire, Epworth Sleepiness Scale, IPAQ, STOP Questionnaire, a PreScreening form, and Medical/Health History were completed prior to participation.
Participants deemed ACSM High risk for cardiovascular disease (2), highly active
lifestyles, and use of heart rate/blood pressure/ blood thinning medications were criteria
for exclusion. Subjects were required to wear an ApneaLink (ResMed; San Diego, CA)
device to measure sleep disturbances by thoracic measurements, oxygen saturation (SpO2),
respiratory effort, and airflow during sleep hours. The Apnea-Hypopnea Index (AHI) was
used to determine the likelihood for OSA in these subjects. Apneas were defined as a
complete cessation in respiration greater than or equal to 10 seconds while hypopnea was
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defined as a decrease in ventilation of at least 50 % with a concomitant reduction of oxygen
saturation. An AHI > 5 is the accepted criteria for diagnosed OSA (53). Subjects recruited
at SRMH Sleep Clinic were evaluated for any known diseases and exclusions which were
reported to the researcher by the on-site physician. All data was collected in the Human
Performance Lab of James Madison University. All written, electronic data and subject
information was stored in a locked file cabinet and password locked laptop in a locked file
cabinet and room within the laboratory. Each participant entering the study completed the
appropriate questionnaires and visited the laboratory three non-consecutive days over the
span of approximately 7 – 10 days.

Treadmill Test
Testing was done in the morning following an overnight fast. A resting blood draw
was administered after 15 minutes of supine rest. Prior to testing, a warm up of 3 to 4
minutes was performed, after which subjects performed two, five minute stages of exercise
at 35% and 70% estimated VO2 reserve. During the test, walking speed and incline level
were adjusted to obtain desired intensity, respectively. Metabolic variables were monitored
continuously using a metabolic measurement system (Parvo Medics; Sandy, UT). Heart
rate was determined continuously via a Polar® heart rate monitor. Immediately following
exercise, a second blood draw was obtained within two minutes of completing the exercise
test.

Blood Sampling and Analysis
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Blood draws were obtained from an antecubital vein after 15 minutes of supine rest
and within two minutes post exercise. Blood was collected in vacutainer tubes containing
heparin, sodium citrate, and acidified citrate. Blood collected in heparin vials was
immediately analyzed for hematocrit using the micro-hematocrit method. Samples
collected in sodium citrate and acidified citrate were spun for 20 minutes at 15000 rpm in
a refrigerated centrifuge. Plasma was extracted from spun samples and stored at -80⁰ C
until analysis. Blood analysis was performed by standardized Enzyme-Linked
Immunosorbent Assay (ELISA) for Factor VIII activity, tPA antigen, tPA activity, and
PAI-1 activity. Post exercise values for all of these variables were corrected for plasma
volume changes using the method described by Van Beaumont et al. (58).

Statistical Analysis
Factor VIII, tPA antigen and activity, and PAI-1 and activity is analyzed using
Repeated Measures Analysis of Variance (ANOVA). OSA and Non-OSA individuals will
be compared using time as a within- subject factor and presence of disease as a between
subject factor from all samples. Post hoc testing was done using paired and independent ttest with a Bonferroni correction factor. Correlation analysis was performed between all
hemostatic variables and age, BMI, and disease severity. A priori statistical significance
was set at P < 0.05. TPA antigen and PAI-1 activity were not normally distributed
according to Shapiro-Wilk, so a log10 transformation was performed prior to these
ANOVAs.
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Abstract
Purpose: To determine the hemostatic response after acute aerobic exercise in Obstructive
Sleep Apnea (OSA). Methods: Eighteen males were recruited from the university and local
community. Individuals who presented evidence of cardiovascular, pulmonary, or
metabolic disease were excluded. Apnea-Hypopnea Index (AHI) > 5 was criteria for OSA.
Subjects performed a treadmill exercise test at 35% and 70% predicted VO2reserve during
the morning hours. Pre exercise blood samples were obtained after 15 minutes supine rest
and within two minutes following exercise. Repeated Measures ANOVA were performed
for Factor VIII antigen, tPA antigen, tPA activity, and PAI-1 activity across two time points
(Pre vs. Post) and between conditions (OSA vs. Controls). Correlational analysis compared
all hemostatic factors with age, BMI, and AHI. Results: Mean AHI was (13.00 + 12.6)
indicating mild OSA severity. There were no exercise x condition interaction for any
observed hemostatic markers (P > 0.05). There was a significant main effect for exercise
in Factor VIII, tPA antigen, and tPA activity in both groups (P < 0.05). There was no main
effect for OSA except an observed trend in PAI-1 which remained elevated after exercise
(P = 0.05). FVIII:Ag and BMI (R = .520), tPA:Ag and AHI (R = .489), and tPA:Ag and
age (R = .496) were positively correlated (P < 0.05). Conclusion: The hemostatic response
after acute aerobic exercise is unaffected in mild OSA although PAI-1 activity seems to be
elevated impacting fibrinolytic potential. BMI seems to correlate with FVIII:Ag, while
AHI and age correlate with tPA:Ag.

Keywords: Hemostasis, Obstructive Sleep Apnea, acute exercise, coagulation, fibrinolysis
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Introduction
OSA is characterized by continuous episodes of arousal during sleep due to complete
or partial cessation of airflow from pharyngeal collapse (30, 36, 22) and affects 2 – 4% of
the middle-aged population (22). Studies have determined that mortality risk, with fatal and
non-fatal events (i.e. traffic accidents), directly increases with AHI severity in sleep
disordered breathing (40, 16). Observational studies show a possible causal relationship
between OSA and atherosclerosis (4, 8, 10). One such study reported that middle-aged
participants without diagnosed cardiovascular disease portrayed early indications of
atherosclerosis (8). Therefore, OSA may have a mechanistic role in the progression of
cardiovascular disease.
Much evidence suggests that an increase in blood coagulation, accompanied with
decreased fibrinolysis, is associated with an increased risk for cardiovascular disease. The
ARIC study found that markers of coagulation potential, Factor VIII and von Willebrand
Factor (vWF), are associated with cardiovascular disease in both men and women (9).
Similarly, the Cardiovascular Heart Study showed Factor VIII is independently associated
with stroke/transient ischemic attacks and coronary heart disease (32). In the Northwick
Park Heart Study, researchers found decreased fibrinolytic activity to be the main
determinant of ischemic heart disease in younger men (18).
Individuals with OSA exhibit an altered hemostatic balance. Specifically, markers
of coagulation are elevated and potential for fibrinolysis is decreased. Von Kanel et al.
observed that plasminogen activator inhibitor 1 (PAI-1), which inhibits tissue plasminogen
activator (tPA), the main stimulus of the fibrinolytic process, correlated with AHI and
oxygen desaturations in subjects with sleep disruptions (35). Furthermore, mice exposed to
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hypoxic conditions experience a greater PAI-1 gene expression with a concomitant increase
in PAI-1 mRNA stability, resulting in greater lung fibrin deposition (23). It has also been
observed that untreated OSA subjects have a shortened whole blood clotting time,
suggesting that OSA is also accompanied with global hypercoagulability (12). Evidence
also suggests that hypoxic conditions result in a shortened coagulation time with a
concurrent rise in Factor VIII (5).
Many instances of myocardial infarction are preceded by physical exertion (11, 21).
During exercise, both coagulation and fibrinolysis increase proportional to intensity (14).
Acil et al. found that persons with coronary artery disease exhibit a hemostatic balance
favoring greater coagulation after an acute bout of exercise (1). This could be
mechanistically linked with exertion-related ischemic events as occlusive thrombi are
responsible for a greater portion of exertion-related events than events triggered by other
causes (11). Although hemostatic responses to exercise are clinically important, these
responses are relatively unknown in obstructive sleep apnea patients. Rangemark et al.
found that OSA subjects exhibited increases in PAI-1 activity with values remaining
significantly elevated before and after 4 minutes of submaximal cycle ergometer exercise
compared to matched controls (24). After exercise, tPA showed a four-fold increase but did
not significantly differ between groups (24). However, this study did not analyze any factors
of coagulation other than platelet activity, which did not significantly change (24). The aim
of this study is to determine if obstructive sleep apnea impacts the Factor VIII, tPA and PAI1 response to acute exercise.
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Methods
Subjects
All subjects gave informed written consent on the study protocol approved by the
James Madison University Institutional Review Board. OSA subjects were recruited from
the JMU community and Sentara Rockingham Memorial Hospital (SRMH) Sleep Clinic.
All SRMH subjects were diagnosed with sleep apnea and not currently using continuous
positive airway pressure (CPAP) as treatment. Eighteen males (> 18 years of age) with
observed sleep problems or significant snoring were recruited for the present study.
Mobility issues, and/or evidence of cardiovascular, pulmonary, and metabolic diseases were
criteria for exclusion in both OSA and Non-OSA groups. Demographic data is presented in
Table 1 for OSA and Normal individuals.
To establish likelihood of Sleep Apnea and screen for exclusion criteria in
community-recruited participants, administration of established sleep surveys including
Berlin Questionnaire, Epworth Sleepiness Scale, IPAQ, STOP Questionnaire, a PreScreening form, and Medical/Health History were completed prior to participation. High
risk for cardiovascular disease, per the American College of Sports Medicine (ACSM)
guidelines (2), highly active lifestyles, and use of heart rate/blood pressure/ blood thinning
medications were criteria for exclusion. Subjects were required to wear an ApneaLink
(ResMed; San Diego, CA) device to measure sleep disturbances by thoracic measurements,
oxygen saturation (SpO2), respiratory effort, and airflow during sleep hours. The ApneaHypopnea Index (AHI) was used to determine the likelihood for OSA in these subjects.
Apneas were defined as a complete cessation in respiration greater than or equal to 10
seconds while hypopnea was defined as a decrease in ventilation of at least 50 % with a
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concomitant reduction of oxygen saturation. An AHI > 5 is the accepted criteria for
diagnosed OSA (30). Subjects recruited at SRMH Sleep Clinic were evaluated for any
known diseases and exclusions which were reported to the researcher by the on-site
physician. All data was collected in the Human Performance Lab of James Madison
University. All written, electronic data and subject information was stored in a locked file
cabinet and password locked laptop in a locked file cabinet and room within the laboratory.
Each participant entering the study completed the appropriate questionnaires and visited the
laboratory three non-consecutive days over the span of approximately 7 – 10 days.

Treadmill Test
Testing was done in the morning following an overnight fast. A resting blood draw
was administered after 15 minutes of supine rest. Prior to testing, a warm up of 3 to 4
minutes was performed, after which subjects performed two, five minute stages of exercise
at 35% and 70% estimated VO2 reserve. During the test, walking speed and incline level
were adjusted to obtain desired intensity, respectively. Metabolic variables were monitored
continuously using a metabolic measurement system (Parvo Medics; Sandy, UT). Heart rate
was determined continuously via a Polar® heart rate monitor. Immediately following
exercise, a second blood draw was obtained within two minutes of completing the exercise
test.

Blood Sampling and Analysis
Blood draws were obtained from an antecubital vein after 15 minutes of supine rest
and within two minutes post exercise. Blood was collected in vacutainer tubes containing
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heparin, sodium citrate, and acidified citrate. Blood collected in heparin vials was
immediately analyzed for hematocrit using the micro-hematocrit method. Samples collected
in sodium citrate and acidified citrate were spun for 20 minutes at 15000 rpm in a
refrigerated centrifuge. Plasma was extracted from spun samples and stored at -80⁰ C until
analysis. Blood analysis was performed by standardized Enzyme-Linked Immunosorbent
Assay (ELISA) for Factor VIII activity, tPA antigen, tPA activity, and PAI-1 activity. Post
exercise values for all of these variables were corrected for plasma volume changes, which
were estimated using the method described by Van Beaumont et al. (33).

Statistical Analysis
Factor VIII, tPA antigen and activity, and PAI-1 activity were analyzed using Repeated
Measures Analysis of Variance (ANOVA). Disease status (OSA vs. Non-OSA) was the
between-subjects factor and exercise (Pre vs. Post) was the within-subject factor. Post hoc
testing was done using paired and independent t-tests with a Bonferroni correction factor.
Correlation analysis was performed between all hemostatic variables and age, BMI, and
disease severity. A priori statistical significance was set at P < 0.05. TPA antigen and PAI1 activity were not normally distributed according to Shapiro-Wilk, so a log10
transformation was performed prior to analysis.
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Results
Eighteen subjects were recruited for the present study. Normal and OSA individuals
were similar in age, height, weight, and BMI. The Apnea-Hypopnea Index was
significantly higher (P < 0.05) in OSA (13.00 + 12.6) than controls (1.44 + 1.33)
respectively indicating mild disease severity in OSA (30). Table 2 presents average VO2
and heart rate values during exercise at 70% predicted VO2 reserve. Oxygen consumption
reached similar levels (P > 0.05) between OSA individuals and controls (28.97 + 7.99
ml/kg/min vs. 25.29 + 5.19, respectively). There were no differences (P > 0.05) in heart
rates during exercise between controls (136.83 + 23.48 bpm) and OSA (128.83 + 19.35
bpm).
Figure 2 displays mean Factor VIII antigen responses to exercise. Factor VIII
antigen significantly (P < 0.05) increased from pre to post exercise in controls (0.84 + 0.30
IU • ml-1 to 1.13 + 0.42 IU • ml-1) and OSA (1.06 + 0.37 IU • ml-1 to 1.15 + 0.31 IU • ml1

). There was no main effect for condition or an exercise x condition interaction.
Mean values for tPA antigen in response to exercise are displayed in Figure 3. Post

exercise values were significantly (P < 0.05) increased in controls (1.18 + 0.81 ng • ml-1 to
1.91 + 1.36 ng • ml-1) and OSA (1.74 + 1.89 ng • ml-1 to 2.87 + 2.87 ng • ml-1). There was
no main effect for condition or an exercise x condition interaction.
Figure 4 displays mean tPA activity responses to exercise. There was no main effect
for condition or an exercise x condition interaction. tPA activity significantly (P < 0.05)
increased post exercise similarly in controls (0.08 + 0.06 IU • ml-1 to 0.78 + 0.35 IU • ml1

) and OSA (0.07 + 0.43 IU • ml-1 to 0.77 + 0.47 IU • ml-1).
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Mean values for PAI-1 activity in response to exercise are displayed in Figure 5. A
trend (P = 0.05) was observed for a main effect of OSA compared to controls (21.35 +
10.65 U • ml-1 to 24.85 + 18.83 U • ml-1 vs. 8.70 + 9.11 U • ml-1 to 8.15 + 7.90 U • ml-1,
respectively). There was no main effect for exercise; nor was there an exercise x condition
interaction (P > 0.05).
Figure 6 displays the correlation between post exercise FVIII antigen and BMI.
There was a significant positive correlation between post exercise FVIII antigen and BMI
(R = .520; P < 0.05). Correlations for pre exercise tPA antigen are presented in Figures 7
and 8. Pre exercise tPA antigen was significantly correlated with AHI (R = .489; P < 0.05)
and age (R = .496; P < 0.05), respectively. No other hemostatic variables were significantly
correlated with AHI, BMI, or age.
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Discussion
The primary finding of the present study is Obstructive Sleep Apnea (OSA) does
not appear to have an effect on the hemostatic response to exercise compared to healthy
individuals. However, OSA may have an effect on resting PAI-1 levels.
Under normal conditions, FVIII increases during exercise in direct proportion to
exercise intensity (14, 6, 3, 37, 20). Because FVIII acts as a coenzyme in relatively small
amounts along the coagulation cascade, an increase in concentration appears to have an
exponential effect in coagulation potential making it a primary variable for study (6).
Further, elevations in FVIII has been associated with increased risk for cardiovascular
disease (CVD) making its evaluation of clinical importance (19, 27, 31). Our data show
similar increases in FVIII antigen in both OSA and normal individuals after acute aerobic
exercise. Currently, there are no known studies describing the coagulation potential after
exercise in OSA. Bartsch et al. showed an increase in FVIII in fifteen army pilots after
hypoxia exposure (5). However, the hypoxia exposure and subsequent oxygen desaturation
levels may not be comparable to OSA. Although there appears to be no differences in the
exercise response of FVIII, an increased coagulation potential may still occur among other
factors along the coagulation cascade. Additionally, post exercise FVIII antigen was
positively correlated with BMI, although there appeared to be no differences in BMI
between groups. Activation of the sympathetic nervous system in larger individuals may
account for this association (6). Indeed, BMI is a risk factor for OSA development (30).
Further, if left untreated, OSA individuals have increased risk of cardiovascular disease
(29, 16, 40, 17). The association of CVD and FVIII levels in OSA should further be
described.
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Recently, Obstructive Sleep Apnea appears to be accompanied with an altered
hemostatic balance at rest (12, 34, 35). Guardiola et al. demonstrated shortened clotting
times in OSA individuals (12) suggesting a pro coagulant imbalance. However, limited
evidence exists for the hemostatic response to exercise in OSA. During exercise,
fibrinolytic potential increases in parallel with coagulation potential (3, 26, 37, 7, 38, 20).
Specifically, increases in tPA antigen and activity are readily observed (7, 38, 20), likely
due to increased sympathetic nervous system activity (6). Our findings suggest that mild
OSA has a similar tPA antigen and activity response to exercise as healthy individuals.
Further, increases in tPA activity after exercise exists in OSA similar to normal subjects,
confirming previous reports (24). Although there are no known studies evaluating tPA
antigen and OSA, it appears that the exercise response is unaffected.
Pre exercise tPA antigen levels were positively associated with OSA severity and
age. Age and tPA antigen have been previously shown to be correlated (28), however the
relationship in OSA is less described. The data suggest OSA severity positively impacts
tPA antigen.

Elevations in tPA antigen have been indicated to increase risk of

cardiovascular disease and acute cardiovascular events (31). Although, individuals in the
present study were classified as having mild disease severity (> 5 - < 15 AHI) (30), we
speculate that this association may contribute to the observed elevated CVD risk at
increasing disease severity (16). The current findings are novel in describing the
relationship of tPA antigen and OSA.
Perhaps the greatest impact on hemostasis in OSA is due to PAI-1 (34, 35, 41). Von
Kanel et al. found elevated PAI-1 levels in OSA (34) with others confirming similar
findings (41). PAI-1 activity also seems to remain elevated after exercise (24). Our findings
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are similar to that of Rangemark et al. (24) showing elevated PAI-1 activity levels in OSA,
unaffected by exercise. Together, mild OSA appears to have an independent effect on PAI1 activity levels potentially lowering fibrinolytic capacity. Acute exercise has been
suggested to temporarily lower PAI-1 in clinical populations thus enhancing chronically
diminished fibrinolytic potential (39, 15). However, this does not appear to occur in lowmoderate intensity exercise in mild OSA. Possible mechanisms may exist that explain the
differences in PAI-1 activity. Pinsky et al. found elevated PAI-1 mRNA in mice
accompanied with greater PAI-1 mRNA stability after sustained exposure to hypoxia (23).
Indeed, Obstructive Sleep Apnea exhibits several short duration episodes of hypoxia during
supine rest (30), however these mechanistic avenues should be further explored. Contrary
to previous findings, there was no observed correlation between PAI-1 activity and AHI
(34). OSA individuals in the present study were classified as mild disease severity, which
may account for the unobserved relationship. Therefore moderate (AHI 15 - < 30) or severe
(AHI > 30) individuals may need to be examined to clarify this association. It is possible,
that greater disease severity accompanied with greater hypoxia exposure, produces this
observed association.
Altered hemostatic balance has been associated with increased risk in developing
cardiovascular disease (13, 9, 18, 31, 32). Specifically, FVIII appears to be elevated in
CVD and is now regarded as a possible risk factor (27, 32). Rumley et al. found increases
in relative odds of ischemic heart disease with increasing concentrations of Factor VIII
(27). Previous studies have shown similar associations (9). Further, impaired fibrinolytic
activity is also associated with increased risk (18). Therefore, the hemostatic variables
evaluated in the present study are of clinical relevance.
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Additionally, many cardiovascular events seem to occur after a period of physical
exertion (21, 11). These events are due mostly to occlusive thrombus formation (3, 20).
Because individuals with OSA already exhibit a hemostatic imbalance (34, 35), the
exercise response is of clinical importance. It appears that mild OSA does not influence
the hemostatic response to low-intensity exercise. However, it is possible fibrinolytic
potential may become compromised either during higher intensity activity (11) or
increasing disease severity (35).
Several limitations exist that may have impacted our findings. Firstly, exercise
intensities were selected based on predictions of VO2 reserve with BMI and self-reported
activity levels (data not shown). Because maximal aerobic capacity was not determined,
variation in predictions could have influenced the current findings. Factor VIII increases
directly proportional to exercise intensity with greater levels achieved during vigorous
exercise (3, 38) while fibrinolytic potential increases even at modest intensity (26).
However, because responses were observed in both groups, the exercise stimulus might
have been sufficient for appropriate comparisons. Additionally, the prescribed exercise was
similar to previous reports, further supporting the current findings (24). Obstructive Sleep
Apnea appeared to have no impact on coagulation potential after exercise. Although FVIII
is unaffected, other factors along the coagulation cascade could be influenced. Robinson et
al. showed no differences in FVIII levels in OSA individuals compared to normal controls
while increases in resting levels of factors XII, VII, and Thrombin anti-thrombin complex
were evident (25). Therefore, future studies will need to evaluate other potential candidates.
The current sample size may also be insufficient, therefore increases in sample size and
disease severity may provide responses or relationships unclear in the current study.
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In conclusion, the hemostatic response after acute exercise is well established.
However evidence of this response in Obstructive Sleep Apnea is limited. Primarily, the
hemostatic changes from acute aerobic exercise are not affected in mild OSA. Rather, PAI1 activity seems to be elevated which remains after exercise showing greater influence of
OSA on fibrinolytic than coagulation potential. Additionally, it appears disease severity,
BMI, and age have some influence on select hemostatic factors in mild OSA individuals.
Currently, the present study adds to the limited data of hemostatic changes and the first to
describe coagulation potential after exercise in Obstructive Sleep Apnea.
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Figure Legend
Figure 1. Overview of Coagulation Cascade

Figure 2. Mean (+ SE) Factor VIII antigen (IU • ml-1) pre exercise and post exercise for
OSA (circles) and controls (squares). * Main effect for exercise (Post > Pre).

Figure 3. Mean (+ SE) tPA antigen (ng • ml-1) pre exercise and post exercise for OSA
(circles) and controls (squares). * Main effect for exercise (Post > Pre).

Figure 4. Mean (+ SE) tPA activity (IU • ml-1) pre exercise and post exercise for OSA
(circles) and controls (squares). * Main effect for exercise (Post > Pre).

Figure 5. Mean (+ SE) PAI-1 activity (AU • ml-1) pre exercise and post exercise for OSA
(circles) and controls (squares). † Main effect for OSA (P = 0.05).

Figure 6. Post Exercise Factor VIII antigen (IU • ml-1) and BMI (kg/m2). *Significant
correlation (P < 0.05).

Figure 7. Pre Exercise tPA antigen (ng • ml-1) and AHI. *Significant correlation (P < 0.05).

Figure 8. Pre Exercise tPA antigen (ng • ml-1) and Age (yrs). *Significant correlation (P <
0.05).
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OSA
Controls
Age (yrs)
45 + 13
38 + 12
Height (cm)
177.87 + 7.18
179.64 + 4.70
Weight (kg)
92.75 + 14.39
88.20 + 10.1
BMI (kg/m2)
29.35 + 3.73
27.39 + 3.24
AHI
13.00 + 12.6*
1.44 + 1.33
Table 1. Subject Demographics. * Significantly different than Controls (P < 0.05).
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VO2 (ml/kg/min)
Heart Rate (bpm)
OSA
25.29 + 5.19
128.83 + 19.35
Controls
28.97 + 7.99
136.83 + 23.48
Table 2. Average VO2 and Heart Rate during Predicted 70% VO2 Reserve.
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Appendices
James Madison University
Department of Kinesiology
Informed Consent
Purpose
You are being asked to volunteer for a research project conducted by Dr. Trent Hargens
from James Madison University entitled, “The effects of obstructive SLEEP apnea on
AUTONOMIC and cardiovascular FUNCTION during steady-state EXERCISE”, or
the SAFE study.
The primary goal of this study is to examine whether individuals who are newly
identified as high risk for, or diagnosed with, obstructive sleep apnea (OSA) show altered
heart rate and cardiovascular variables during sub-maximal exercise. This may provide a
clearer picture into why OSA increases the risk for other chronic health problems.
Experimental Procedures
You will be asked to visit the Human Performance Laboratory (HPL) in Godwin Hall 3
times over the course of about 7 – 10 days. Your total time commitment for participation
in this study will be approximately 2 and a half hours. In addition, you will be asked to
wear (for one night) an at-home sleep testing device (the ApneaLink) to screen you for
possible OSA. It is equipped with straps, a finger probe, and a nasal cannula. It measures
your breathing activity, heart rate, and blood oxygen levels, and is harmless to wear. If
you have previously been diagnosed with OSA through Sentara RMH, then you will not
have to wear the ApneaLink device. Also, you will be asked to wear a device (an
accelerometer) on your waist during the day for a period of 4 days, including 1 weekend
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day, while wearing the same device on your wrist at night while you sleep. Detailed
information on each visit is provided below:
Visit 1
Before any test is given, you will be asked to complete a screening form and an informed
consent, to insure that you meet the study criteria, that you do not have any factors that
would disqualify you from participation. Upon completion of the informed consent, you
will be asked to complete a short health history questionnaire providing information
about your characteristics and health. You will then be asked complete 3 standardized
questionnaires about snoring, the quality of your sleep, daytime sleepiness, and risk for
OSA.
You will then have your height, weight, waist circumference and neck circumference
measured. After that, your body composition will be analyzed via a Dual-energy x-ray
absorptiometer (DEXA). The DEXA scan will allow us to measure your percent body fat
and the mineral content and density of your bones. The DEXA is much like an X-ray
machine. The DEXA will scan your entire body very slowly; so, you will need to lie on a
table without moving for almost 10 minutes, while the DEXA is passed over your entire
body. You will feel no discomfort associated with this test.
At the end of this first visit you will also be instructed on the proper use procedures for
wearing the ApneaLink device for your one-night sleep assessment, as well as
instructions on wearing the accelerometer. An accelerometer is a small device that is to
be worn on your waist during the day and on your wrist while in bed.
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Following the DEXA scan, we will ask that you wear a heart rate monitor while lying
down in a darkened room for 15 minutes to get measures of your heart rate. We will also
obtain your resting blood pressure.
Visit 2
The following day after Visit 1, you will be asked to return to the HPL to return the
ApneaLink device. Following this, we will ask that you wear a heart rate monitor while
lying down in a darkened room for 15 minutes to get measures of your heart rate. We
will also obtain your resting blood pressure. This visit should take about 30 minutes.
Visit 3
Approximately 5 – 6 days later, you will be asked to return to the HPL for your final
visit. For this visit you will undergo a submaximal treadmill exercise test. You will be
asked to walk on the treadmill for a total of about 15 minutes, which includes a 3 – 4
minute warm-up, and 2 – 3 minute cool-down. In between the warm-up and cool-down
you will be asked to walk at 2 separate workloads, 1 fairly easy and 1 somewhat hard, for
5 minutes at each workload. During this test we will monitor the electrical output of your
heart by placing electrodes directly on your skin across your chest, stomach and back.
During the test, we will measure the electrical activity of your heart, your heart rate,
blood pressure, your effort, and how much oxygen your body is using. To see how much
oxygen you use, we will ask you to breathe into a rubber mouthpiece. During the test,
you will breathe only through the mouthpiece and may experience some dryness in your
mouth. Prior to your arrival to the HPL for this visit, you will be asked to consume a
normal meal (breakfast or lunch) and not to come to the HPL with a full stomach.
Caffeine should be avoided the day of your exercise trial. We will obtain about 10 ml of
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blood (about 2 teaspoons) prior to and immediately after the exercise trial in order to
determine the potential of your blood to coagulate. These blood samples will be obtained
from an arm vein.
Follow-up testing
If you are shown to have OSA, and you undergo treatment for OSA through continuous
positive airway pressure treatment (CPAP), you will be asked to undergo repeat testing of
all previously described tests (except for the ApneaLink device) after 6 months of
treatment. If you are shown to not have OSA, follow-up testing will not be done.
Risks
There are no risks associated with wearing an accelerometer. Also, there is no risk
associated with heart rate, blood pressure, height, weight, and waist and neck
circumference measures. You will not be asked to change any of your personal habits
during the course of the study. Measurements with associated risks include: the DEXA
scan and treadmill exercise test.
The amount of radiation that you will receive in the DEXA exam is less than the amount
you will receive during a transatlantic flight, and is equal to about 1/20 of a chest x-ray.
You should not be pregnant for this study because of risks from the DEXA scan radiation
to the embryo or fetus. If you feel that you might be pregnant, inform the research staff
immediately.
There is a risk of abnormal changes during the submaximal treadmill exercise test. These
changes may include abnormal blood pressure, fainting, heart rhythm disorders, stroke,
heart attack, and death. The chance of serious heart problems during maximal exercise
among adults is very small (less than 1/10,000 maximal exercise tests)._ENREF_10 The
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exercise trial for this proposed study is sub-maximal vs. maximal, so the risk for
complications is even less. Every effort will be made to minimize risks of an abnormal
response by reviewing you health history and providing adequate supervision of the
exercise test. All staff are certified by the American Heart Association in BLS (Basic
Life Support).
With the blood draw, there is the risk of discomfort, bruising, and, in rare instances,
infection, lightheadedness, and fainting. We will use sterile procedures and trained
personnel to minimize discomfort and complications.
Benefits
Participation may include knowledge about your health status. You will receive
information on your body composition, including percent body fat and bone mineral
density, an assessment of your sleep quality and risk for sleep apnea, an assessment of
your physical activity level, and cardiovascular fitness. In addition, a $50 stipend is
provided for subjects who complete the study protocol. Indirect benefits of participating
in this study will be helping the researchers better understand the relationship between
sleep apnea and cardiovascular disease risk.
Inquiries
If you have any questions or concerns or you would like to receive a copy of the final
aggregate results of this study, please contact Dr. Trent Hargens at hargenta@jmu.edu or
(540) 568-5844.
Questions about Your Rights as a Research Subject
Dr. David Cockley

Dr. Stewart Pollock

Chair, Institutional Review Board

Chair, Institutional Review Board
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James Madison University

Sentara RMH Medical Center

(540) 568-2834

(540) 689-1000

cocklede@jmu.edu

SGPOLLO3@SENTARA.com

Confidentiality
All data and results will be kept confidential. You will be assigned an identification code.
At no time will your name be identified with your individual data. The researcher retains
the right to use and publish non-identifiable data. All data will be kept secured in a
locked cabinet. All electronic data will be kept on a password-protected computer. Final
aggregate results will be made available to participants upon request.
Freedom of Consent
Your participation is entirely voluntary. You are free to choose not to participate.
Should you choose to participate, you can withdraw at any time without consequences of
any kind.
I have read this consent form and I understand what is being requested of me as a
participant in this study. I freely consent to participate. I have been given satisfactory
answers to my questions. The investigator provided me with a copy of this form. I
certify that I am at least 18 years of age.
________________________________

__________________________________

Name of Subject (Printed)

Name of Researcher (Printed)

________________________________

__________________________________

Name of Subject (Signed)

Name of Researcher (Signed)

________________________________

__________________________________

Date

Date
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Medical and Health History Form
Name:

Date of Birth: ________________

Ethnicity:
Height:

ft

Weight:

Gender: Female

pounds

Male

Campus Address:
Campus Telephone Number: ____________________ Campus Email Address:
_____________________
Address

for

Permanent

Residence:

________________________________________________________
Person

to

contact

in

case

of

emergency:

_____________________________________________________
Relationship: _____________

Daytime Telephone: ____________

Home

Telephone:
Primary Care Physician:

________________________

Telephone:

Medical History
Please indicate any current or previous conditions or problems you have experienced or
have been told by a physician you have had:
Yes

No

Heart disease or any heart problems:

_____

_____

Rheumatic fever:

_____

_____

Respiratory disease or breathing problems:

_____

_____
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Circulation problems:

_____

_____

Kidney disease or problems:

_____

_____

Urinary problems:

_____

_____

Reproductive problems:

_____

_____

Musculoskeletal problems:

_____

_____

Fainting or dizziness, especially with exertion:

_____

_____

Neurological problems/disorders:

_____

_____

High blood pressure:

_____

_____

Low blood pressure:

_____

_____

High blood cholesterol:

_____

_____

Diabetes:

_____

_____

Thyroid problems:

_____

_____

Eating disorders (bulimia, anorexia):

_____

_____

Allergies:

_____

_____

If "yes" to any of the above please indicate the date, explain, and describe:

Please list any hospitalizations/operations/recent illnesses (Type/Date):
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Do you ever feel faint, short of breath, or chest discomfort with exertion? Yes: ________
No: ________
If "yes", please explain :

Are there any orthopedic limitations you have that may restrict your ability to perform
hard running exercise or intense strength-type exercises? (back, hips, knees, ankles)
Yes

No _____

If "yes" please explain:

Family Health History
Has anyone in your family (blood relatives only) been diagnosed or treated for any of the
following?
Yes

No

Relationship

Age

Heart attack

_____

_____

_____

Heart disease

_____

_____

_____

High blood pressure _____

_____

_____

Stroke

_____

_____

_____

Kidney disease

_____

_____

_____

Diabetes

_____

_____

_____
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Health Habits
Do you add salt to your food? Yes ___ No ___ Are you on any special type of diet?
Yes ___ No ___
If "yes" please describe

Do you drink caffeinated beverages? Yes _____ No ______

Do you drink alcoholic beverages?

Yes _____

How many cups per day?

No ______ How many drinks per

week? _________
What is the average number of drinks that you consume on the weekend? _________
Did you use tobacco products in the past (more than 12 months ago)? Yes ______

No

_______
Sleep Habits Evaluation
Do you have episodes of parasomnias (disorders such as sleep walking, sleep talking, night
terrors, body rocking, bedwetting that will cause partial or full awakening?) Yes
No
Do you show signs of sleep disturbances (such as insomnia, daytime sleepiness) when you
are anxious, stressed?

Yes

No

Do you have difficulties to fall asleep if a certain object or a certain situation is absent such
as listening to the radio, watching the television, etc?

Yes

No

Do you have difficulties to fall asleep earlier or later of your usual bedtime? Yes
No
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Do you wake up at night to get a little snack? Yes

No

If “yes”, do you think that the snack is helping you to go back to sleep? Yes

No

Do you have hallucinations (vivid images that look like dreams occurring when you sleep)
or find yourself physically weak or paralyzed for a few seconds?

Yes

No
Tonsils and Adenoids evaluation questionnaire
Do you have a history of recurrent tonsillitis which is an inflammation of the tonsils
(clusters of tissue that lie in bands on both sides of the back of the throat) caused by an
infection? In tonsillitis, the tonsils are enlarged, red, and often coated either partly or
entirely? Yes

No

Did you ever have inflammation of the adenoids (single clump of tissue in the back of the
nose) causing a

blockage of the back of the nose, chronic and recurrent fluid or

infections of your ears, or chronic or recurrent sinus infections?

Yes

No
Did you have tonsillectomy (tonsils removed) or adenoidectomy (adenoids removed)? Yes
No
Medications
Please list all medications (prescription and over-the-counter) you are currently taking or
have taken in the past week:

______
__________________________
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________________________________________________________________________
____________
________________________________________________________________________
____________

Please sign to indicate the above information is correct:
____
Print Name

Signature

Follow Up Review and Interview by:
____________________________________
Signature of Project Staff Member

Date

Date
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Subject Prescreening Information

Please complete the Following:
Age (yrs):
Height (inches):
Weight (lbs):
Average Exercise Habits over the Past 2 Months:
Avg. # days of exercise per week:
Avg. # of days of aerobic exercise per week:
Avg. # of days of resistance exercise per week:
Do you currently use medications of any kind?
Have you previously been diagnosed with a heart or lung disease?
Do you have diabetes?
Have you previously been diagnosed with Obstructive Sleep Apnea?
If yes, are you currently being treated for it?
Snoring
Do you snore?
If yes, do you snore: (circle one)
1 Day per week
2-4 Days per week
5 or greater Days per week
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SAFE Study Exercise Protocol Data Sheet
Subject ID________________________
Age _______ Age pred. max HR ________ 85% APMHR ________
35% of Predicted VO2 Reserve________________
VO2Reserve______________

70% of Predicted

Ht (in) ______ Wt (kg) ______ (lbs) _______ Resting HR ___________(seated)
___________ (standing)
Resting BP: Seated:___________________
Standing:_____________________________

Time
Warm-up
1
Warm-up
2
Stage 1
1
2
3
4
5
Stage 2
6
7
8
9
10
Recovery
1
2
3
4
5

Speed/Grade

HR
(bpm)

BP
mmHg

RPE

Signs/Symptoms

2.0 / 0%
2.0 / 0%
/
/
/
/
/
/

*

/
/
/
/

*

*

*

2.0 / 0%

Comments:
________________________________________________________________________
VO2 Stage 1: ________ mL/kg/min
VO2 Stage 2: _________ mL/kg/min
METs Stage 1: _______
METs Stage 2: ________
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